2-amino-5-[[1-(carboxymethylamino)-3-(diethylcarbamoylsulfanyl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-amino-5-[[1-(carboxymethylamino)-3-(diethylcarbamoylsulfanyl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
• 化学式: C₁₅H₂₆N₄O₇S
• 分子量: 406.5
• InChiKey: WZXBYDBYBIGAQN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.6
• 重原子数：
  27
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  204
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• [EN] SALT FORMS OF S-(N, N-DIETHYLCARBAMOYL)GLUTATHIONE<br/>[FR] FORMES SALINES DE S-(N, N-DIÉTHYLCARBAMOYL)GLUTATHION
  申请人：TONIX PHARMA HOLDINGS LTD

  公开号：WO2020194058A1

  公开（公告）日：2020-10-01

  The invention relates in various aspects to a salt form S-(N, N-diethylcarbamoyl)glutathione, a method of producing the salt form, a pharmaceutical composition comprising said salt form. The invention also relates to a method of preventing or treating a glutamate-related disorder comprising administering to said subject a therapeutically effective amount of said salt form.

  该发明涉及盐形式S-(N,N-二乙基氨甲酰)谷胱甘肽的各种方面，一种制备该盐形式的方法，包括所述盐形式的药物组合物。该发明还涉及一种预防或治疗谷氨酸相关疾病的方法，包括向所述受试者投予所述盐形式的治疗有效量。
• Method for treatment of glutamate related disorders
  申请人：——

  公开号：US20010031730A1

  公开（公告）日：2001-10-18

  Disclosed are novel compounds and novel pharmaceutical compositions for use in medical therapy, as well as intermediates and processes for preparing such compounds. Therapeutic methods for preventing or treating glutamate-related disorders in a mammal and methods to inhibit or prevent glutamate binding in mammalian tissue are also disclosed.

  本发明涉及新型化合物和新型药物组合物，用于医疗治疗，以及制备这些化合物的中间体和过程。还公开了在哺乳动物中预防或治疗谷氨酸相关疾病的治疗方法，以及抑制或预防哺乳动物组织中谷氨酸结合的方法。
• Therapeutic compositions
  申请人：Schloss V. John

  公开号：US20050130904A1

  公开（公告）日：2005-06-16

  A method is provided for the preparation of compounds of the formula (R 1 )(R 2 )NC(═X)S(O) n R 3 or (R 1 )(R 2 )NC(═X)OS(O) n R 3 , wherein R 1 , R 2 and R 3 , X and n have any of the meanings defined in the specification. A method is also provided for the detection and quantitation of compounds of the formula (R 1 )(R 2 )NC(═X)OS(O) n R 3 . A method to link a therapeutic agent to a compound that is conjugated to glutathione is also provided for the purpose of improving the therapeutic properties of the therapeutic agent. Novel compounds, intermediates, pharmaceutical compositions and methods of use are also provided.

  提供了一种制备式（R 1 )(R 2 )NC(═X)S(O) n R 3 或（R 1 )(R 2 )NC(═X)OS(O) n R 3 其中 R 1 , R 2 和 R 3 X 和 n 具有说明书中定义的任何含义。还提供了一种检测和定量式（R 1 )(R 2 NC(═X)OS(O) n R 3 .为了改善治疗剂的治疗特性，还提供了一种将治疗剂与谷胱甘肽共轭的化合物连接的方法。还提供了新型化合物、中间体、药物组合物和使用方法。
• SALT FORMS OF S-(N, N-DIETHYLCARBAMOYL)GLUTATHIONE
  申请人：Tonix Pharma Holdings Limited

  公开号：EP3946601A1

  公开（公告）日：2022-02-09
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURONAL INJURY
  申请人：AXCELLA HEALTH INC.

  公开号：US20190046486A1

  公开（公告）日：2019-02-14

  This disclosure provides compositions and methods for treating or preventing neuronal injury in a subject, e.g., a subject at risk of or having traumatic brain injury or stroke.